35
Participants
Start Date
October 23, 2018
Primary Completion Date
January 5, 2022
Study Completion Date
January 5, 2022
Prazosin
Oral prazosin HCl capsules (or placebo) will be administered twice daily, with individualized doses up to a maximum of 4 mg QAM mid-morning and 6 mg at bedtime (QHS), or matching placebo capsules
Placebo oral capsule
Placebo capsule matched to appearance of active drug.
VAMC: James J Peters, The Bronx
SUNY Upstate Medical University, Syracuse
Roper St. Francis Hospital, Charleston
University of Kentucky, Lexington
University of Texas, Health Science Center San Antonio, San Antonio
Banner Sun Health Research Institute, Sun City
University of Southern California, Los Angeles
University of California, San Diego (UCSD), San Diego
Alta California Medical Group, Simi Valley
Stanford University, Stanford
Oregon Health and Science University, Portland
University of Washington, Seattle
Northern Light/Acadia Hospital Eastern Maine Medical Center, Bangor
University of Washington, Seattle
National Institute on Aging (NIA)
NIH
VA Puget Sound Health Care System
FED
Alzheimer's Association
OTHER
Alzheimer's Disease Cooperative Study (ADCS)
OTHER